Timothy Edward Lee Sells 18,425 Shares of Invivyd (NASDAQ:IVVD) Stock

Key Points

• Invivyd insider Timothy Edward Lee sold 18,425 shares at an average price of $0.84, generating $15,477. The sale reduced his holdings by 9.34% and was conducted to cover tax obligations from vested equity awards.
• Invivyd shares recently traded around $0.87, with a market capitalization of approximately $256 million. The company reported a quarterly loss of $0.14 per share, missing estimates, alongside $14.29 million in revenue.
• Analyst sentiment is mixed, with the stock carrying an overall “Hold” rating and an average price target of $8.00. Institutional investors own about 70.36% of the company, while several funds recently increased their positions.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Timothy Edward Lee sold 18,425 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $15,477.00. Following the completion of the transaction, the insider owned 178,937 shares of the company's stock, valued at approximately $150,307.08. This trade represents a 9.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Timothy Edward Lee also recently made the following trade(s):

• On Monday, August 17th, Timothy Edward Lee sold 22,355 shares of Invivyd stock. The shares were sold at an average price of $0.72, for a total transaction of $16,095.60.

Invivyd Stock Performance

Shares of NASDAQ:IVVD traded up $0.13 during mid-day trading on Tuesday, reaching $0.87. 7,732,095 shares of the company's stock were exchanged, compared to its average volume of 3,061,089. Invivyd, Inc. has a twelve month low of $0.48 and a twelve month high of $3.07. The firm has a market capitalization of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The business's fifty day moving average price is $0.77 and its 200-day moving average price is $1.23.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The company had revenue of $14.29 million during the quarter, compared to analyst estimates of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. Analysts predict that Invivyd, Inc. will post -0.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on IVVD. Wall Street Zen cut Invivyd from a "hold" rating to a "strong sell" rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Invivyd in a research note on Friday, July 24th. HC Wainwright reiterated a "buy" rating on shares of Invivyd in a report on Tuesday. Finally, BTIG Research reiterated a "buy" rating on shares of Invivyd in a report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Invivyd currently has an average rating of "Hold" and an average price target of $8.00.

Hedge Funds Weigh In On Invivyd

Institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its holdings in shares of Invivyd by 190.6% during the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company's stock worth $66,000 after buying an additional 71,485 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company's stock worth $249,000 after buying an additional 391,617 shares during the period. Marshall Wace LLP acquired a new position in shares of Invivyd during the 2nd quarter valued at $158,000. Jane Street Group LLC acquired a new position in shares of Invivyd during the 2nd quarter valued at $147,000. Finally, Vanguard Group Inc. boosted its stake in Invivyd by 46.7% during the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company's stock worth $6,339,000 after acquiring an additional 1,834,970 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source